カテゴリ： GlobalData, アメリカ, 企業調査

Zogenix Inc (ZGNX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Zogenix Inc (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9826
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：64
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Zogenix Inc (Zogenix) is a pharmaceutical company with focus on central nervous system (CNS) disorders. It develops and commercializes therapies for rare CNS disorders. The company’s lead product candidate ZX008 (low dose fenfluramine) is intended for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS). ZX008 is in Phase 3 clinical trials and has orphan drug designation in the US and EU and secured Fast Track designation and breakthrough therapy designation from the US FDA. The company operates in the UK through its subsidiary Zogenix International, Ltd. Zogenix is headquartered in Emeryville, California, the US.

Zogenix Inc (ZGNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zogenix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Zogenix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 12
Zogenix Amends Co-Marketing Agreement With Battelle Memorial Institute For DosePro 13
Licensing Agreements 14
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 14
Zogenix International Amends Licensing Agreement with University of Antwerp and University of Leuven 15
Equity Offering 16
Zogenix Prices Public Offering of Shares for USD312 Million 16
Zogenix Raises USD289 Million in Public Offering of Shares 18
Zogenix Raises USD98.3 Million in Public Offering of Shares 20
Zogenix Raised USD10.8 Million in Public Offering Of Shares 22
Zogenix Completes Public Offering Of Shares For US$69 Million 23
Zogenix Completes Public Offering Of Units For US$70 Million 25
Asset Transactions 26
Pernix Acquires Zohydro ER Business from Zogenix 26
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 28
Acquisition 29
Zogenix Acquires Brabant Pharma for USD130 Million 29
Zogenix Inc – Key Competitors 30
Zogenix Inc – Key Employees 31
Zogenix Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 06, 2018: Zogenix provides corporate update and reports second quarter financial results 33
May 09, 2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results 35
Mar 06, 2018: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 37
Nov 07, 2017: Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results 39
Aug 08, 2017: Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results 41
May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 43
Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 44
Corporate Communications 46
Jul 02, 2018: Zogenix Appoints Ashish Sagrolikar As New Global Chief Commercial Officer 46
Jan 05, 2017: Zogenix Announces CFO Transition 47
Product News 48
05/22/2017: Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry 48
02/06/2018: Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome 49
Product Approvals 50
Jun 22, 2017: Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome 50
Mar 01, 2017: Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome 51
Clinical Trials 52
Jan 31, 2018: Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome 52
Dec 04, 2017: Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase III Clinical Trial of ZX008 in Dravet Syndrome 53
Nov 29, 2017: Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome 55
Nov 28, 2017: Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4 56
Nov 21, 2017: New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting 57
Oct 16, 2017: Zogenix Provides Update on ZX008 59
Sep 29, 2017: Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome 60
May 04, 2017: Zogenix Provides Update On Phase 3 Study Of ZX008 61
Apr 27, 2017: Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome 62
Feb 13, 2017: Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Zogenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zogenix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Zogenix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 12
Zogenix Amends Co-Marketing Agreement With Battelle Memorial Institute For DosePro 13
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 14
Zogenix International Amends Licensing Agreement with University of Antwerp and University of Leuven 15
Zogenix Prices Public Offering of Shares for USD312 Million 16
Zogenix Raises USD289 Million in Public Offering of Shares 18
Zogenix Raises USD98.3 Million in Public Offering of Shares 20
Zogenix Raised USD10.8 Million in Public Offering Of Shares 22
Zogenix Completes Public Offering Of Shares For US$69 Million 23
Zogenix Completes Public Offering Of Units For US$70 Million 25
Pernix Acquires Zohydro ER Business from Zogenix 26
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 28
Zogenix Acquires Brabant Pharma for USD130 Million 29
Zogenix Inc, Key Competitors 30
Zogenix Inc, Key Employees 31
Zogenix Inc, Other Locations 32
Zogenix Inc, Subsidiaries 32

List of Figures
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zogenix Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Zogenix Inc (ZGNX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Inchcape plc (INCH)：企業の財務・戦略的SWOT分析
    Inchcape plc (INCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Gaia, Inc. (GAIA)：企業の財務・戦略的SWOT分析
    Gaia, Inc. (GAIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Epigenomics AG (ECX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • Absorption Systems LP-医療機器分野：企業M&A・提携分析
    Summary Absorption Systems LP (Absorption Systems) is a pre-clinical contract research organization that develops and implements research tools. The organization carries out preclinical testing of drugs, biologics, and medical devices. It develops and implements research tools to predict human outco …
  • HeidelbergCement AG：企業のM&A・事業提携・投資動向
    HeidelbergCement AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HeidelbergCement AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Karolinska Development AB (KDEV)：企業の財務・戦略的SWOT分析
    Summary Karolinska Development AB (Karolinska Development) is a life sciences investment company that develops innovations from science into commercial products. The company invests in start up's and growth of the pharmaceutical, medical device and biotechnology companies that develop specialty care …
  • CytomX Therapeutics Inc (CTMX)：製薬・医療：M&Aディール及び事業提携情報
    Summary CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company which develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, probody drug conjuga …
  • BioMarin Pharmaceutical Inc (BMRN)：企業の財務・戦略的SWOT分析
    BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • NCC Ltd (NCC)：企業の財務・戦略的SWOT分析
    NCC Ltd (NCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • RainDance Technologies Inc：医療機器：M&Aディール及び事業提携情報
    Summary RainDance Technologies Inc (RDT), a subsidiary of Bio-Rad Laboratories Inc is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA; …
  • European Institute of Oncology-製薬・医療分野：企業M&A・提携分析
    Summary European Institute of Oncology (IEO) is a research institute that conducts clinical and scientific research on cancer prevention, early diagnosis and treatment of cancer. The institute offers medical care services for breast tumors, lung tumors, cervical tumors, endometrial tumors, thoracic …
  • Schaffer Corporation Limited (SFC)：企業の財務・戦略的SWOT分析
    Schaffer Corporation Limited (SFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • OriGene Technologies Inc-製薬・医療分野：企業M&A・提携分析
    Summary OriGene Technologies Inc (OriGene) is a research tool company that develops cDNA. The company creates commercial collection of full-length human cDNAs in expression vector. It develops, manufactures and sells genome research and diagnostic products. OriGene’s products include qPCR reagents, …
  • Shinva Medical Instrument Co Ltd (600587)：企業の財務・戦略的SWOT分析
    Shinva Medical Instrument Co Ltd (600587) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • MEC Resources Ltd (MMR)：企業の財務・戦略的SWOT分析
    MEC Resources Ltd (MMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Sao Martinho SA (SMTO3)：企業の財務・戦略的SWOT分析
    Sao Martinho SA (SMTO3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • YTL Corporation Berhad：企業の戦略・SWOT・財務分析
    YTL Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary YTL Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Scomi Group Bhd (SCOMI)：企業の財務・戦略的SWOT分析
    Scomi Group Bhd (SCOMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Oxiteno SA Industria E Comercio：企業の戦略的SWOT分析
    Oxiteno SA Industria E Comercio - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Novanta Inc (NOVT)：医療機器：M&Aディール及び事業提携情報
    Summary Novanta Inc (Novanta), formerly GSI Group Inc is a medical device company that manufactures and markets precision photonics, motion control components and subsystems. The company provides laser products, medical technologies, and precision motion products. It offers laser sources and beam de …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆